Arcutis Biotherapeutics vs HUTCHMED (China)
ARQT and HCM side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ARQT and HCM compare
Arcutis Biotherapeutics grew revenue faster over the last twelve months (60.0% versus −13.0% for HUTCHMED (China)).
HUTCHMED (China) keeps more of each dollar of sales as profit, with a net margin of 83.3% compared with 5.9% at Arcutis Biotherapeutics.
Arcutis Biotherapeutics scores higher on the StockData Score (11 against 5 for HUTCHMED (China)), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ARQT | HCM |
|---|---|---|
| Size and price | ||
| Market cap | $3.6B | – |
| Share price | $28.26 | $14.90 |
| Change, 1 year | 20.5% | −2.5% |
| Change, 5 years | 55.4% | −51.5% |
| Beta (5Y) | 0.92 | 0.97 |
| Employees | 354 | 109 |
| StockData Score | ||
| Total score | 11 (better) | 5 |
| Valuation score | 0 | 0 |
| Growth score | 4 (better) | 0 |
| Performance score | 4 (better) | 3 |
| Health score | 3 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 128× | – |
| P/S | 7.0× | – |
| P/B | 14.6× | – |
| EV/EBITDA | 96.7× | – |
| P/FCF | 59.5× | – |
| FCF yield | 1.7% | – |
| Fair value | $6.04 | – |
| Margin of safety | −368% | – |
| Growth | ||
| Revenue growth (TTM) | 60.0% (better) | −13.0% |
| Revenue growth, 5Y average | – | 19.2% |
| Net income growth (TTM) | – | 1111% |
| EPS growth (TTM) | – | 1200% |
| Profitability | ||
| Gross margin | 91.2% (better) | 38.7% |
| Operating margin | 6.9% (better) | −7.1% |
| Net margin | 5.9% | 83.3% (better) |
| FCF margin | 11.7% (better) | −14.4% |
| Return on equity | 14.9% | 36.7% (better) |
| Return on invested capital | 32.9% | – |
| Financial health | ||
| Debt / equity | 0.45 | 0.09 (better) |
| Net debt / EBITDA | −4.27 | – |
| Interest coverage | 2.6× (better) | −13.7× |
| Current ratio | 2.92 | 5.64 (better) |
| Altman Z-score | 6.54 | – |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 105% | 0.51% |
| Held by insiders | 9.3% | 0.44% |
| Insider net buying, 12 months | −$11.1M | – |
| Short interest, % of float | 15.9% | – |
Go deeper
- ARQT stock overview
- ARQT income statement
- ARQT valuation and score
- HCM stock overview
- HCM income statement
- HCM valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.